BioNTech to Present Oncology Data at ESMO 2024
Ticker: BNTX · Form: 6-K · Filed: Sep 5, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Sep 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: oncology, clinical-trials, esmo, pipeline-update
TL;DR
BioNTech dropping new oncology trial data at ESMO Sept 27-30.
AI Summary
On September 5, 2024, BioNTech SE announced its intention to present clinical trial data for several oncology pipeline assets. The presentations will occur at the European Society for Medical Oncology (ESMO) Congress 2024, taking place from September 27-30, 2024, in Spain. This event is a significant platform for showcasing advancements in cancer research and treatment.
Why It Matters
The presentation of clinical trial data at a major oncology congress like ESMO is crucial for BioNTech to demonstrate the progress and potential of its drug candidates to the scientific community and investors.
Risk Assessment
Risk Level: low — This filing is an announcement of upcoming data presentation, not a financial event or material change in business operations.
Key Players & Entities
- BioNTech SE (company) — Registrant
- European Society for Medical Oncology (ESMO) Congress 2024 (company) — Event where data will be presented
- September 5, 2024 (date) — Date of announcement
- September 27-30, 2024 (date) — Dates of ESMO Congress
FAQ
What specific clinical trial data will BioNTech SE present at ESMO 2024?
The filing states that BioNTech SE will present clinical trial data for selected assets from its multi-platform oncology pipeline, but does not specify which assets or trials.
When and where will the ESMO Congress 2024 take place?
The ESMO Congress 2024 will take place from September 27-30, 2024, in Spain.
What is the purpose of BioNTech SE filing this Form 6-K?
This Form 6-K is being filed to report the announcement that BioNTech SE will present clinical trial data at the ESMO Congress 2024.
Is BioNTech SE required to file annual reports on Form 20-F or 40-F?
Yes, BioNTech SE indicates it files annual reports under cover of Form 20-F.
What is BioNTech SE's primary business classification?
BioNTech SE's Standard Industrial Classification is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with the code 2836.
Filing Stats: 265 words · 1 min read · ~1 pages · Grade level 15 · Accepted 2024-09-05 08:53:58
Filing Documents
- form6-kesmo20245sep2024.htm (6-K) — 15KB
- a99_1240905xbntxprxesmo202.htm (EX-99.1) — 44KB
- image_0.jpg (GRAPHIC) — 15KB
- 0001776985-24-000079.txt ( ) — 80KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On September 5, 2024, BioNTech SE announced that it will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (ESMO) Congress 2024 in Barcelona, Spain from September 13-17, 2024. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Jens Holstein By s Dr. Sierk Poetting Name Jens Holstein Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date September 5, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024